Lipton A, Santner S J, Santen R J, Harvey H A, Feil P D, White-Hershey D, Bartholomew M J, Antle C E
Cancer. 1987 Feb 15;59(4):779-82. doi: 10.1002/1097-0142(19870215)59:4<779::aid-cncr2820590419>3.0.co;2-u.
Aromatase activity was measured in 104 primary and 24 metastatic breast cancer patients. The assay employed quantitates the production of 3H water release from 1 beta-[3H]androstenedione after aromatization. Of 104 human primary breast tumors studied, 64 contained measurable aromatase activity, ranging from 5-70.5 pmol estrone formed/g protein/hour. In primary breast cancers there was no difference in levels of aromatase activity when analyzed by menstrual status or age by decade. Aromatase activity was similar in small and large primary tumors. The median aromatase activity of primary breast tumors (8.6 pmol/g/h) was similar to that found in metastatic breast cancer deposits (12.0 pmol/g/h). Aromatase activity did not correlate with either estrogen (ER) or progesterone (PR) receptor concentration in the tissues assayed. In this regard there were 33 ER- PR- tumor biopsies. Twelve of these 33 tumors contained aromatase activity greater than 10 pmol/g/hour.
对104例原发性乳腺癌患者和24例转移性乳腺癌患者进行了芳香化酶活性检测。该检测方法通过定量测定1β-[3H]雄烯二酮芳香化后3H水的释放量来进行。在研究的104例人类原发性乳腺肿瘤中,64例含有可测量的芳香化酶活性,范围为每克蛋白质每小时形成5 - 70.5皮摩尔雌酮。在原发性乳腺癌中,按月经状态或每十年的年龄分析时,芳香化酶活性水平没有差异。小的和大的原发性肿瘤中的芳香化酶活性相似。原发性乳腺肿瘤的芳香化酶活性中位数(8.6皮摩尔/克/小时)与转移性乳腺癌病灶中的相似(12.0皮摩尔/克/小时)。在检测的组织中,芳香化酶活性与雌激素(ER)或孕激素(PR)受体浓度均无相关性。在这方面,有33例ER - PR - 肿瘤活检样本。这33例肿瘤中有12例的芳香化酶活性大于10皮摩尔/克/小时。